时间：10月12日（星期四） 下午13: 30
报告人：David C. Muddiman博士，美国北卡罗莱纳州立大学教授
David C. Muddiman is the Jacob and Betty Belin Distinguished Professor of Chemistry and Founder and Director of the W.M. Keck FTMS Laboratory for Human Health Research at North Carolina State University in Raleigh, NC. Prior to moving his research group to North Carolina State University in 2006, David was a Professor of Biochemistry and Molecular Biology and Founder and Director of the Proteomics Research Center at the Mayo Clinic College of Medicine in Rochester, MN. Prior to this appointment, David was an Associate Professor of Chemistry at Virginia Commonwealth University. It was there that he began his professional career as an assistant professor with an adjunct appointment in the Department of Biochemistry and Molecular Biophysics andas a member of the Massey Cancer Centerin 1997. These academic appointments followed a postdoctoral fellowship at Pacific Northwest National Laboratory in the Environmental Molecular Sciences Laboratory under Richard D. Smith from 1995-1997. David was born in Long Beach, CA in 1967 but spent most of his formative years in a small town in Pennsylvania. David received his B.S. in chemistry from Gannon University (Erie, PA) in 1990 and his Ph.D. in Analytical Chemistry from the University of Pittsburgh in 1995 under the auspices of David M. Hercules. Dr. Muddiman is Editor of Analytical and Biological Chemistry and Associate Editor of the Encyclopedia of Analytical Chemistry as well as on the Editorial Advisory Board of Mass Spectrometry Reviews, Molecular and Cellular Proteomics, Rapid Communications in Mass Spectrometry, and the Journal of Chromatography B. He also serves on the advisory board of the NIH Funded Complex Carbohydrate Research Center, University of Georgia and the Yale/NIDA Neuroproteomics Center, Yale University. Dr. Muddiman has served as a member of the ASMS Board of Directors and Treasurer of US-HUPO, and he is currently the President of US HUPO. His group has presented over 500 invited lectures and presentations at national and international meetings including 20 plenary/keynote lectures. His group has published over 250 peer-reviewed papers and has received four US patents in addition to two patents pending. He is the recipient of the 2015 ACS Award in Chemical Instrumentation, 2010 Biemann Medal (American Society for Mass Spectrometry), 2009 NCSU Alumni Outstanding Research Award, the 2004 ACS Arthur F. Findeis Award, the 1999 American Society for Mass Spectrometry Research Award, and the 1990-1991 Safford Awardfor Excellence in Teaching (University of Pittsburgh). Dr. Muddiman’s research is at the intersection of innovative mass spectrometry technologies, systems biology, and model organisms for diseases and bioenergy, and is funded by the National Institutes of Health, the National Science Foundation, the Department of Energy, and The United States Department of Agriculture.
Mass spectrometry offers the most robust platform to discover and characterize new diagnostic, prognostic, and therapeutic biomarkers for ovarian cancer across all molecular classes. Moreover, a systems biology approach will allow the underlying biology of ovarian cancer to be understood. This presentation will discuss the challenges specific to the study of epithelial ovarian cancer (EOC) in humans and how these challenges have directed our thinking, in terms of the development of model organisms and mass spectrometry-based bioanalytical strategies. First, to augment the human model, we developed the domestic hen model of spontaneous EOC, which allowed us to longitudinally sample the rapid onset and progression of the disease in a controlled environment. Second, we developed bioanalytical tools to characterize structurally challenging analytes that are critical to a systems-level analysis. To increase the electrospray response of N-linked glycans, perform stable-isotope relative quantification, and semi-automated data analysis, we synthesized novel hydrophobic tagging reagents(INLIGHTTM). Furthermore, we developed a novel ionization technique for tissue imaging of lipids and metabolites. This unique model organism has and continues to provide new insights into the biology of ovarian cancer; combined with other –OMICS data obtained through these novel bioanalytical approaches, we will understand the origin of ovarian cancer and ultimately translate that knowledge to humans.